Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury

Digestion

Volumn 84, Issue 1, 2011, Pages 54-59

  Wree, Alexander ^a   Dechêne, Alexander ^a   Herzer, Kerstin ^a   Hilgard, Phillip ^a   Syn, Wing Kin ^b   Gerken, Guido ^a   Canbay, Ali ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Acute liver failure; Drug induced liver injury; Ursodesoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; BILIRUBIN GLUCURONIDE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; LACTATE DEHYDROGENASE; LIVER ANTIGEN; PREDNISONE; SERUM ALBUMIN; SMOOTH MUSCLE ANTIBODY; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER BIOPSY; LIVER FAILURE; LIVER INJURY; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TISSUE INJURY; TOXIC HEPATITIS; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ANTI-INFLAMMATORY AGENTS; BIOPSY; CHOLAGOGUES AND CHOLERETICS; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; LIVER FAILURE, ACUTE; LIVER FUNCTION TESTS; MALE; PREDNISONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 79551650561     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000322298     Document Type: Review

References (44)

1. Bénichou C: Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990; 11: 272-276.
2. Björnsson E: The natural history of drug-induced liver injury. Semin Liver Dis 2009; 29: 357-363.
3. Zimmerman HJ: Drug-induced liver disease. Clin Liver Dis 2000; 4: 73-96 (Pubitemid 33041487) (Pubitemid 33041487)
4. Björnsson E, Olsson R: Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42: 481-489. (Pubitemid 41061102) (Pubitemid 41061102)
5. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García- Munoz B, González-Grande R, Pizarro A, Durán JA, Jiménez M, Rodrigo L, Romero- Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salmerón J, Martin-Vivaldi R: Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521. (Pubitemid 41096639) (Pubitemid 41096639)
6. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J: Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-1934, 1934.e1-4.
7. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SHB, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM: Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-954. (Pubitemid 35440240) (Pubitemid 35440240)
8. Wei G, Bergquist A, Broomé U, Lindgren S, Wallerstedt S, Almer S, Sangfelt P, Danielsson A, Sandberg-Gertzén H, Lööf L, Prytz H, Björnsson E: Acute liver failure in Sweden: etiology and outcome. J Intern Med 2007; 262: 393-401. (Pubitemid 47246972) (Pubitemid 47246972)
9. de Abajo FJ, Montero D, Madurga M, García Rodríguez LA: Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58: 71-80. (Pubitemid 38901470) (Pubitemid 38901470)
10. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, Hillon P: Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-455. (Pubitemid 34810366) (Pubitemid 34810366)
11. Canbay A, Jochum C, Bechmann LP, Festag S, Gieseler RK, Yüksel Z, Lütkes P, Saner FH, Paul A, Gerken G: Acute liver failure in a metropolitan area in Germany: a retrospective study (2002-2008). Z Gastroenterol 2009; 47: 807-813.
12. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, Reisch JS, Schiodt FV, Ostapowicz G, Shakil AO, Lee WM: Acetaminophen- induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42: 1364-1372. (Pubitemid 43260039) (Pubitemid 43260039)
13. Kaplowitz N: Drug-induced liver injury. Clin Infect Dis 2004; 38(suppl 2):S44-S48 (Pubitemid 38328164) (Pubitemid 38328164)
14. Rakela J, Mosley JW, Edwards VM, Govindarajan S, Alpert E: A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group. Dig Dis Sci 1991; 36: 1223-1228.
15. European Association for the Study of the Liver (EASL): Randomised trial of steroid therapy in acute liver failure. Gut 1979; 20: 620-623.
16. Spagnuolo MI, Iorio R, Vegnente A, Guarino A: Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. Gastroenterology 1996; 111: 716-719. (Pubitemid 26293237) (Pubitemid 26293237)
17. Katsinelos P, Vasiliadis T, Xiarchos P, Patakiouta F, Christodoulou K, Pilpilidis I, Eugenidis N: Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin-clavulanate potassium (Augmentin)-induced intra-hepatic cholestasis: report of two cases. Eur J Gastroenterol Hepatol 2000; 12: 365-368. (Pubitemid 30168594) (Pubitemid 30168594)
18. Frieß G, Wienbeck M: Cholestatischer Ikterus nach Einnahme von Amoxicillin und Clavulansäure. Dtsch Med Wochenschr 2008; 120: 1356-1360.
19. Piotrowicz A, Polkey M, Wilkinson M: Ursodeoxycholic acid for the treatment of flucloxacillin- associated cholestasis. J Hepatol 1995; 22: 119-120.
20. Singh C, Bishop P, Willson R: Extreme hyperbilirubinemia associated with the use of anabolic steroids, health/nutritional supplements, and ethanol: response to ursodeoxycholic acid treatment. Am J Gastroenterol 1996; 91: 783-785. (Pubitemid 26117964) (Pubitemid 26117964)
21. Mörk H, al-Taie O, Klinge O, Scheurlen M: Successful therapy of persistent androgeninduced cholestasis with ursodeoxycholic acid. Z Gastroenterol 1997; 35: 1087-1091. (Pubitemid 28067995) (Pubitemid 28067995)
22. Habscheid W, Abele U, Dahm HH: Schwere Cholestase mit Nierenversagen durch Anabolika bei einem Bodybuilder. Dtsch med Wochenschr 2008; 124: 1029-1032.
23. Kneiseler G, Bachmann H, Bechmann L, Dechene A, Heyer T, Baba H, Saner F, Jochum C, Gerken G, Canbay A: A rare case of propofol-induced acute liver failure and literature review. Case Rep Gastroenterol 2010; 4: 57-65.
24. Beard K, Belic L, Aselton P, Perera DR, Jick H: Outpatient drug-induced parenchymal liver disease requiring hospitalization. J Clin Pharmacol 1986; 26: 633-637. (Pubitemid 17183529) (Pubitemid 17183529)
25. Meier Y, Cavallaro M, Roos M, Pauli-Magnus C, Folkers G, Meier PJ, Fattinger K: Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005; 61: 135-143. (Pubitemid 40674746) (Pubitemid 40674746)
26. Fontana RJ, Seeff LB, Andrade RJ, Björnsson E, Day CP, Serrano J, Hoofnagle JH: Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010; 52: 730-742.
27. Canbay A, Chen S, Gieseler RK, Malago M, Karliova M, Gerken G, Broelsch CE, Treichel U: Overweight patients are more susceptible for acute liver failure. Hepatogastroenterology 2005; 52: 1516-1520. (Pubitemid 41391028) (Pubitemid 41391028)
28. Kaplowitz N: Mechanisms of liver cell injury. J Hepatol 2000; 32: 39-47.
29. Kaplowitz N: Cell death at the millennium. Implications for liver diseases. Clin Liver Dis 2000; 4: 1-23, v. (Pubitemid 33041484) (Pubitemid 33041484)
30. Bechmann LP, Jochum C, Kocabayoglu P, Sowa J, Kassalik M, Gieseler RK, Saner F, Paul A, Trautwein C, Gerken G, Canbay A: Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol 2010; 53: 639-647.
31. Rodrigues CM, Fan G, Wong PY, Kren BT, Steer CJ: Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 1998; 4: 165-178. (Pubitemid 28223968) (Pubitemid 28223968)
32. Palmer RH: Bile acids, liver injury, and liver disease. Arch Intern Med 1972; 130: 606-617.
33. Perez M, Briz O: Bile-acid-induced cell injury and protection. World J Gastroenterol 2009; 15: 1677-1689.
34. DeLeve LD, Wang X, Kuhlenkamp JF, Kaplowitz N: Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology 1996; 23: 589-599. (Pubitemid 26087175) (Pubitemid 26087175)
35. Odin JA, Huebert RC, Casciola-Rosen L, LaRusso NF, Rosen A: Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. J Clin Invest 2001; 108: 223-232. (Pubitemid 32656246) (Pubitemid 32656246)
36. Liu Z, Kaplowitz N: Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6: 755-774.
37. Sánchez-Osorio M, Duarte-Rojo A, Martínez- Benítez B, Torre A, Uribe M: Anabolicandrogenic steroids and liver injury. Liver Int 2008; 28: 278-282.
38. Veneri RJ, Gordon SC: Anabolic steroid-induced cholestasis: choleretic response to corticosteroids. J Clin Gastroenterol 1988; 10: 467-468.
39. Krishnan PV, Feng Z, Gordon SC: Prolonged intrahepatic cholestasis and renal failure secondary to anabolic androgenic steroidenriched dietary supplements. J Clin Gastroenterol 2009; 43: 672-675.
40. Bispo M, Valente A, Maldonado R, Palma R, Glória H, Nóbrega J, Alexandrino P: Anabolic steroid-induced cardiomyopathy underlying acute liver failure in a young bodybuilder. World J Gastroenterol 2009; 15: 2920-2922.
41. Stimac D, Milić S, Dintinjana RD, Kovac D, Ristić S: Androgenic/anabolic steroid-induced toxic hepatitis. J Clin Gastroenterol 2002; 35: 350-352.
42. Gurakar A, Caraceni P, Fagiuoli S, Van Thiel DH: Androgenic/anabolic steroid-induced intrahepatic cholestasis: a review with four additional case reports. J Okla State Med Assoc 1994; 87: 399-404.
43. Danan G, Benichou C: Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330. (Pubitemid 23333873) (Pubitemid 23333873)
44. Benichou C, Danan G, Flahault A: Causality assessment of adverse reactions to drugs. II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-1336. (Pubitemid 23333874) (Pubitemid 23333874)